ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,638.94
2.13%
Dow Jones
41,488.19
1.65%
US Dollar vs MXN
19.9285
-0.79%
Brent Oil
70.285
0.51%
Bitcoin
84,000.00
3.74%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Theravance Biopharma Inc (TBPH)

  7. Theravance Biopharma Inc (TBPH) Noticias

TBPH

Theravance Biopharma (TBPH)

Theravance Biopharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TBPH
FechaHoraFuenteTítuloSímboloCompañía
07/03/202505:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TBPHTheravance Biopharma Inc
04/03/202517:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
26/02/202515:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
26/02/202515:05PR Newswire (US)Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TBPHTheravance Biopharma Inc
20/02/202505:00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
12/02/202505:00PR Newswire (US)Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025NASDAQ:TBPHTheravance Biopharma Inc
21/01/202515:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TBPHTheravance Biopharma Inc
17/12/202405:00PR Newswire (US)Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceNASDAQ:TBPHTheravance Biopharma Inc
14/11/202408:53Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
14/11/202405:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TBPHTheravance Biopharma Inc
12/11/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValueNASDAQ:TBPHTheravance Biopharma Inc
24/10/202405:00PR Newswire (US)Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024NASDAQ:TBPHTheravance Biopharma Inc
18/10/202408:00PR Newswire (US)Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseaseNASDAQ:TBPHTheravance Biopharma Inc
05/08/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
22/07/202405:00PR Newswire (US)Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024NASDAQ:TBPHTheravance Biopharma Inc
11/06/202415:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
13/05/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
29/04/202405:00PR Newswire (US)Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:TBPHTheravance Biopharma Inc
10/04/202405:00PR Newswire (US)Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024NASDAQ:TBPHTheravance Biopharma Inc
26/02/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
16/02/202419:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
14/02/202415:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TBPHTheravance Biopharma Inc
14/02/202405:00PR Newswire (US)Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024NASDAQ:TBPHTheravance Biopharma Inc
05/01/202405:00PR Newswire (US)Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)NASDAQ:TBPHTheravance Biopharma Inc
21/12/202316:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TBPHTheravance Biopharma Inc
21/12/202316:00PR Newswire (US)Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of DirectorsNASDAQ:TBPHTheravance Biopharma Inc
18/12/202305:00PR Newswire (US)Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare ConferenceNASDAQ:TBPHTheravance Biopharma Inc
16/11/202305:00PR Newswire (US)Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous SystemNASDAQ:TBPHTheravance Biopharma Inc
15/11/202305:00PR Newswire (US)Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TBPHTheravance Biopharma Inc
13/11/202307:00PR Newswire (US)Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)NASDAQ:TBPHTheravance Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:TBPH

Su Consulta Reciente

NYSE
VZ
Verizon Communications
FX
EURUSD
Euro vs US Dollar
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
COIN
XRPUSD
Ripple
COIN
AVAXUSD
Avalanche
SPI
SP500
S&P 500
NASDAQ
TSLA
Tesla
COIN
ADAUSD
Cardano
AMEX
XLV
Health Care Select Sector
FX
USDMXN
US Dollar vs MXN
AMEX
SPY
SPDR S&P 500
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios